In the EWALL-PH-01 study (Table 1) about tyrosine kinase inhibitors (TKIs) in managing Ph-positive ALL, administration of dasatinib with a low-intensity asparaginase-containing regimen in older patients resulted in favorable outcomes [31]. The gene discussed is ASPG; the disease is acute lymphoblastic leukemia.